Low-risk prostate cancer and low testosterone: What are the acceptable alternatives?

[21] Hoffman M.A., DeWolf W.C., Morgentaler A., Is low serum free testosterone a marker for high grade prostate cancer?, J Urol, 163, pp. 824-827, (2000)

[22] Yamamoto S., Yonese J., Kawakami S., Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy, Eur Urol, 52, pp. 696-701, (2007)

[23] Ribeiro M., Ruff P., Falkson G., Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer, Am J Clin Oncol, 20, pp. 605-608, (1997)

[24] Kaufman J.M., Graydon R.J., Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men, J Urol, 172, pp. 920-922, (2004)

[25] Agarwal P.K., Oefelein M.G., Testosterone replacement therapy after primary treatment for prostate cancer, J Urol, 173, pp. 533-536, (2005)

[26] Sarosdy M.F., Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy, Cancer, 109, pp. 536-541, (2007)

[27] Khera M., Lipshultz L.I., The role of testosterone replacement therapy following radical prostatectomy, Urol Clin North Am, 34, pp. 549-553, (2007)

[28] Morgentaler A., Testosterone therapy for men at risk for or with history of prostate cancer, Curr Treat Options Oncol, 7, pp. 363-369, (2006)

[29] Morgentaler A., Testosterone replacement therapy and prostate cancer, Urol Clin North Am, 34, pp. 555-563, (2007)

[30] Rhoden E.L., Morgentaler A., Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia, J Urol, 170, pp. 2348-2351, (2003)

[21] Hoffman M.A., DeWolf W.C., Morgentaler A., Is low serum free testosterone a marker for high grade prostate cancer?, J Urol, 163, pp. 824-827, (2000)

[22] Yamamoto S., Yonese J., Kawakami S., Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy, Eur Urol, 52, pp. 696-701, (2007)

[23] Ribeiro M., Ruff P., Falkson G., Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer, Am J Clin Oncol, 20, pp. 605-608, (1997)

[24] Kaufman J.M., Graydon R.J., Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men, J Urol, 172, pp. 920-922, (2004)

[25] Agarwal P.K., Oefelein M.G., Testosterone replacement therapy after primary treatment for prostate cancer, J Urol, 173, pp. 533-536, (2005)

[26] Sarosdy M.F., Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy, Cancer, 109, pp. 536-541, (2007)

[27] Khera M., Lipshultz L.I., The role of testosterone replacement therapy following radical prostatectomy, Urol Clin North Am, 34, pp. 549-553, (2007)

[28] Morgentaler A., Testosterone therapy for men at risk for or with history of prostate cancer, Curr Treat Options Oncol, 7, pp. 363-369, (2006)

[29] Morgentaler A., Testosterone replacement therapy and prostate cancer, Urol Clin North Am, 34, pp. 555-563, (2007)

[30] Rhoden E.L., Morgentaler A., Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia, J Urol, 170, pp. 2348-2351, (2003)